Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration

February 26, 2010

Article

Eye advance online publication 12 February 2010; doi: 10.1038/eye.2010.9

Eye advance online publication 12 February 2010; doi: 10.1038/eye.2010.9

Purpose: To assess the 1-year functional outcome and to evaluate the morphological changes after intravitreal injections of ranibizumab in eyes affected with retinal angiomatous proliferation (RAP) due to age-related macular degeneration (AMD).

Related Content

UVC light can be used as a noninvasive treatment for microbial keratitis. Image courtesy of Photon Therapeutics. Concept image for cornea treatment with ultraviolet light.

The future of microbial keratitis treatment is bright

Priyanka Mandal, MBChB FRCOphth;Sunil Shah, MBBS, FRCS(Ed), FRCOphth, FBCLA, FWCRS

April 29th 2025

Article

Ultraviolet light’s potential in ocular care extends beyond structural reinforcement to antimicrobial applications, especially for microbial keratitis

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD

July 22nd 2024

Podcast

A woman in a surgical mask, covering her nose and mouth, rubs her eyes. Concept image for autoimmune disease correlation to dry eye disease. Image credit: ©Prostock-studio – stock.adobe.com

Diagnosing types of dry eye in patients with autoimmune disease

Lynda Charters

April 24th 2025

Article

A young boy with glasses reading a book. Concept image for atropine drop paediatric myopia treatment approval in India. Image credit: ©WESTOCK – stock.adobe.com

ENTOD Pharmaceuticals announces CDSCO approval of 0.05% atropine drops (Myatro XL)

Hattie Hayes;Emily Kaiser Maharjan;Jordana Joy

April 23rd 2025

Article

According to a press release, Myatro XL is the first 0.05% atropine eye drop for paediatric myopia control.

A red light with an alarm symbol. It reads "SOS." Concept image for emergency, medical emergency, neurology and ophthalmology referral. Image credit: ©Nicole Kwiatkowski – stock.adobe.com

Investigating causes of diplopia to minimise morbidity and mortality

Lynda Charters

April 23rd 2025

Article

Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions

A photo of a boardroom with a presenter's projector screen, and easel, and many chairs. Concept image for Beth Marsh appointed CCO chief commercial officer of Neurotech Pharmaceuticals, ophthalmic industry news update. Image credit: ©nnpp's Images – canva.com

Neurotech appoints Beth Marsh as chief commercial officer ahead of US product launch

Kassi Filkins

April 22nd 2025

Article

The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)

Related Content

The future of microbial keratitis treatment is bright

Priyanka Mandal, MBChB FRCOphth;Sunil Shah, MBBS, FRCS(Ed), FRCOphth, FBCLA, FWCRS

April 29th 2025

Article

Ultraviolet light’s potential in ocular care extends beyond structural reinforcement to antimicrobial applications, especially for microbial keratitis

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD

July 22nd 2024

Podcast

Diagnosing types of dry eye in patients with autoimmune disease

Lynda Charters

April 24th 2025

Article

ENTOD Pharmaceuticals announces CDSCO approval of 0.05% atropine drops (Myatro XL)

Hattie Hayes;Emily Kaiser Maharjan;Jordana Joy

April 23rd 2025

Article